LUNG Key Statistics, Chart & Performance
The current stock price of LUNG is 1.775 USD. In the past month the price decreased by -21.49%. In the past year, price decreased by -68.49%.
LUNG Technical Analysis
LUNG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LUNG. LUNG has a bad profitability rating. Also its financial health evaluation is rather negative.
LUNG Financial Highlights
Over the last trailing twelve months LUNG reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS increased by 1.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.04% | ||
| ROE | -94.54% | ||
| Debt/Equity | 0.62 |
LUNG Forecast & Estimates
12 analysts have analysed LUNG and the average price target is 5.87 USD. This implies a price increase of 230.42% is expected in the next year compared to the current price of 1.775.
For the next year, analysts expect an EPS growth of -7.1% and a revenue growth 8.99% for LUNG
LUNG Ownership
About LUNG
Company Profile
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 291 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Company Info
PULMONX CORP
700 Chesapeake Dr
Redwood City CALIFORNIA 94063 US
CEO: Glendon E. French
Employees: 291
Phone: 16509342600
PULMONX CORP / LUNG FAQ
What does LUNG do?
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 291 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Can you provide the latest stock price for PULMONX CORP?
The current stock price of LUNG is 1.775 USD. The price decreased by -0.84% in the last trading session.
What is the dividend status of PULMONX CORP?
LUNG does not pay a dividend.
How is the ChartMill rating for PULMONX CORP?
LUNG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for LUNG stock?
PULMONX CORP (LUNG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.41).
Can you provide the growth outlook for PULMONX CORP?
The Revenue of PULMONX CORP (LUNG) is expected to grow by 8.99% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is PULMONX CORP worth?
PULMONX CORP (LUNG) has a market capitalization of 73.22M USD. This makes LUNG a Micro Cap stock.